OTC · CRXTQ
Clarus Therapeutics Holdings, Inc.
Healthcare · Drug Manufacturers - General
$0.00
Up+$0.00 (+0.00%)
Updated Aug 24, 2026, 7:54 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 72.83K
- P/E ratio
- -0
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 38.26K
- Avg. volume
- 122.28K
Price performance
CRXTQ price history
1M range · 0 trading sessions · Daily adjusted prices
CRXTQ does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest CRXTQ news
The latest Smart Investors Daily articles mentioning CRXTQ.
Stock researchCompany · Overview
CRXTQ research
Overview
Company profile and research snapshot.
Company profile
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois. On September 5, 2022, Clarus Therapeutics Holdings, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
